1.jpg)
CSRA Inc.’s wholly-owned subsidiary, DynPort Vaccine Company LLC (DVC), received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to manage a variety of medical product development initiatives for the National Institute of Allergy and Infectious Diseases (NIAID). CSRA’s DynPort Vaccine Company is one of four awardees to receive the IDIQ valued up to $159 million, with a period of performance of up to 10 years.
Under the contract, the company will develop manufacturing processes and analytical test methods, perform product characterization, conduct manufacturing following current good manufacturing practices (cGMP) and provide regulatory services to support the development of new therapies to treat infectious diseases. NIAID is part of the National Institutes of Health and focuses on understanding, treating and preventing infectious, immunologic and allergic diseases that impact our nation and the world.
“DVC has been successfully conducting product development for government agencies for nearly 20 years,” said Gary S. Nabors, Ph.D., president, DynPort Vaccine Company LLC. “Together with our teaming partners, we have the talent and experience base to conduct the wide array of medical product development activities needed by our customer. NIAID has been at the forefront of implementing new therapies, vaccines, diagnostic tests and other technologies that have improved the lives of millions of people around the world and we are honored to support their efforts.”
This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
Dvc receives, contract from niaid, advance development, medical products
